Congye Wu1, Yehong Liu2, Feiyue Shi2, Fei Chen2, Yongcai Zhao3, Huanyu Zhao4. 1. Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. 2. Department of Oncology and Radiotherapy, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. 3. Department of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. 13852293317@163.com. 4. Department of Oncology and Radiotherapy, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. oncodoc1@sina.com.
Abstract
OBJECTIVE: The aim of this study was to analyze the relationship of serum gastrin-17 (G-17) and oral mucositis in head and neck carcinoma (HNC) patients receiving radiotherapy. METHODS: Serum G-17 were detected in patients before and after radiotherapy. Patients were divided into high G-17 group (baseline serum G-17 ≥ 5pmol/L) and low G-17 group (baseline serum G-17 < 5pmol/L). The severity of oral mucositis was analyzed between the two groups. Other complications such as dysphagia, salivary gland, mandible, thyroid function, larynx, pain, and weight loss were also investigated. RESULTS: Forty-two patients were analyzed in this study. The level of serum G-17 had a significant decrease after radiotherapy (7.29 ± 5.70pmol/L versus 4.93 ± 4.46pmol/L, P = 0.038). In low serum G-17 group, the incidences of grade 0, 1-2 and 3-4 of oral mucositis were 0%, 30.4%, and 69.6%, respectively. In high serum G-17 group, the incidences of grade 0, 1-2 and 3-4 of oral mucositis were 0%, 63.2%, and 36.8%, respectively. Pearson correlation analysis showed that serum G-17 was negatively correlated with oral mucositis (r=-0.595, P < 0.01). Weight loss of low G-17 group was more serious than that of high G-17 group. CONCLUSION: Serum G-17 has a close relationship with oral mucositis. Baseline serum G-17 may be a potential predictor for the severity of oral mucositis in HNC patients receiving radiotherapy.
OBJECTIVE: The aim of this study was to analyze the relationship of serum gastrin-17 (G-17) and oral mucositis in head and neck carcinoma (HNC) patients receiving radiotherapy. METHODS: Serum G-17 were detected in patients before and after radiotherapy. Patients were divided into high G-17 group (baseline serum G-17 ≥ 5pmol/L) and low G-17 group (baseline serum G-17 < 5pmol/L). The severity of oral mucositis was analyzed between the two groups. Other complications such as dysphagia, salivary gland, mandible, thyroid function, larynx, pain, and weight loss were also investigated. RESULTS: Forty-two patients were analyzed in this study. The level of serum G-17 had a significant decrease after radiotherapy (7.29 ± 5.70pmol/L versus 4.93 ± 4.46pmol/L, P = 0.038). In low serum G-17 group, the incidences of grade 0, 1-2 and 3-4 of oral mucositis were 0%, 30.4%, and 69.6%, respectively. In high serum G-17 group, the incidences of grade 0, 1-2 and 3-4 of oral mucositis were 0%, 63.2%, and 36.8%, respectively. Pearson correlation analysis showed that serum G-17 was negatively correlated with oral mucositis (r=-0.595, P < 0.01). Weight loss of low G-17 group was more serious than that of high G-17 group. CONCLUSION: Serum G-17 has a close relationship with oral mucositis. Baseline serum G-17 may be a potential predictor for the severity of oral mucositis in HNC patients receiving radiotherapy.
Authors: Rajesh V Lalla; Michael T Brennan; Sharon M Gordon; Stephen T Sonis; David I Rosenthal; Dorothy M Keefe Journal: J Natl Cancer Inst Monogr Date: 2019-08-01
Authors: Pentti Sipponen; Matti Vauhkonen; Timo Helske; Ilpo Kaariainen; Matti Harkonen Journal: World J Gastroenterol Date: 2005-10-14 Impact factor: 5.742
Authors: Daniel E Johnson; Barbara Burtness; C René Leemans; Vivian Wai Yan Lui; Julie E Bauman; Jennifer R Grandis Journal: Nat Rev Dis Primers Date: 2020-11-26 Impact factor: 52.329